{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:42Z","timestamp":1790351682235,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ijantimicag.2017.09.016","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T07:17:08Z","timestamp":1507792628000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013\u20132015)"],"prefix":"10.1016","volume":"51","author":[{"given":"M.A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.09.016_bib0010","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cir475","article-title":"Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections\u2014proceedings and data from the Gram-Negative Resistance Summit","volume":"53","author":"Kollef","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0025","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2013.280695","article-title":"Report reveals scope of US antibiotic resistance threat","volume":"310","author":"Hampton","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0030","series-title":"Antimicrobial resistance surveillance report Europe 2013","author":"European Center for Disease Prevention and Control","year":"2014"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0035","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.47102\/annals-acadmedsg.V37N10p819","article-title":"Antibiotic resistance in Gram-negative bacilli: a Singapore perspective","volume":"37","author":"Tan","year":"2008","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0045","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-3156.2011.02822.x","article-title":"Antimicrobial susceptibility of bacterial isolates from community acquired infections in sub-Saharan Africa and Asian low and middle income countries","volume":"16","author":"Ashley","year":"2011","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0732-8893(01)00353-4","article-title":"Prevalence of extended spectrum \u03b2-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998\u201399)","volume":"42","author":"Bell","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijantimicag.2011.01.009","article-title":"High burden of antimicrobial resistance in Asia","volume":"37","author":"Jean","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2013.01.005","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010)","volume":"76","author":"Sader","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.09.016_bib0065","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0075","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/CCM.0000000000001140","article-title":"Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis","volume":"43","author":"Zhang","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0080","first-page":"787","article-title":"Critical evaluation of ceftolozane\u2013tazobactam for complicated urinary tract and intra-abdominal infections","volume":"12","author":"Giancola","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0090","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jhin.2005.07.009","article-title":"Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital","volume":"62","author":"Daxboeck","year":"2006","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0095","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 \u00d7 \u201820 progress\u2014development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0100","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0110","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u20132012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0120","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0125","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0130","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0135","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jinf.2010.03.024","article-title":"The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)","volume":"60","author":"Farrell","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2005.04.004","article-title":"Regional variation in the prevalence of extended-spectrum \u03b2-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998\u20132002)","volume":"52","author":"Hirakata","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0924-8579(02)00050-X","article-title":"Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific region: report from the SENTRY Antimicrobial Surveillance Program, 1998\u20131999","volume":"20","author":"Turnidge","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jinf.2011.02.009","article-title":"Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria","volume":"62","author":"Chen","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","article-title":"The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance","volume":"25","author":"Jones","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2009.06.003","article-title":"Increasing extended-spectrum \u03b2-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia\/Pacific region: data from the SMART study 2002\u20132006","volume":"59","author":"Ko","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.09.016_bib0175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T01:04:43Z","timestamp":1693098283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917303643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0924857917303643"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.09.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013\u20132015)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}